Hyaluronic Acid as A Biomarker for Liver Fibrosis in Chronic Hepatitis “C” Patients

Document Type : Original Article

Authors

Department of Tropical Medicine, El-Minia Faculty of Medicine

Abstract

Introduction: Because of that and its short half-life in blood (2–5 min), serum HA levels can 
reflect liver fibrosis stage and were incorporated into a long list of serum noninvasive liver 
fibrosis markers such as procollagen III N-terminal propeptide (PIIINP), laminin and 
transforming growth factor beta (TGF-b) (Afdhal NH, Nunes D., 2004). It was found that 
serum levels of hyaluronic acid are elevated in chronic liver diseases in which the serum 
levels of ECM would be changed. These include alcoholic and non-alcoholic steatohepatitis, 
hepatitis B, C and others (Rostami S, et al., 2013). Patient And Methods: This study was 
designed to evaluate the effect of antiviral therapy on the serum hyaluronic acid as 
abiomarker of fibrosis ;in patients with chronic hepatitis C. Results: We found that serum 
hyaluronic acid level showed asignificant decrease after treatment. Recommendations: 
Hyaluronic acid can be used to determine the stage of fibrosis when liver biopsy is 
contraindicated.

Keywords

Main Subjects

Files

Share

How to cite

Statistics